In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma.
CAR-T cell therapy offers superior survival and lower treatment-related deaths compared to stem cell transplant for relapsed lymphoma.
Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma. In conclusion, axi-cel provided superior PFS and OS to patients with r/r LBCL compared with allo-HCT, primarily due to lower treatment-related mortality and improved disease control in patients with c.
What the study was
- Study design
- Cohort study
- Population
- Patients with r/r large b-cell lymphoma
- Sample size
- 187
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clin Lymphoma Myeloma Leuk
Why it surfaced
Flag NOVEL_TREATMENT promotes to HIGH priority for this cohort study on Hematologic malignancies, Novel therapeutics: immunotherapy, CAR-T, targeted therapy (score 7/10).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.